Evidence map›Paper›PMID 31743887›Full record

ArticleRedox biology2020

Phenotypic screen for oxygen consumption rate identifies an anti-cancer naphthoquinone that induces mitochondrial oxidative stress.

Frances L Byrne, Ellen M Olzomer, Gabriella R Marriott, Lake-Ee Quek, Alice Katen, Jacky Su, Marin E Nelson, Gene Hart-Smith, Mark Larance, Veronica F Sebesfi and 15 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Redox biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Chemopreventive Effects ofCurrent issues in molecular biology · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Frances L ByrneSchool of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW, Australia. Electronic address: frances.byrne@unsw.edu.au.
Ellen M OlzomerSchool of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW, Australia.
Gabriella R MarriottSchool of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW, Australia.
Lake-Ee QuekSchool of Mathematics and Statistics, The University of Sydney, Sydney, Australia.
Alice KatenSchool of Chemistry, University of New South Wales, Sydney, NSW, Australia.
Jacky SuSchool of Chemistry, University of New South Wales, Sydney, NSW, Australia.
Marin E NelsonCharles Perkins Centre, School of Life and Environmental Sciences, University of Sydney, Australia.
Gene Hart-SmithSchool of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW, Australia.
Mark LaranceCharles Perkins Centre, School of Life and Environmental Sciences, University of Sydney, Australia.
Veronica F SebesfiSchool of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW, Australia.
Jeff CuffSchool of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW, Australia.
Gabriella E MartynSchool of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW, Australia.
Elizabeth ChildressDepartment of Chemistry and VT Center for Drug Discovery, Virginia Tech, Blacksburg, VA, USA.
Stephanie J AlexopoulosSchool of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW, Australia.
Ivan K PoonDepartment of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC, Australia.
Maree C FauxWalter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Antony W BurgessWalter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Glen ReidConcord Medical School, Asbestos Disease Research Institute, University of Sydney, Australia.
Joshua A McCarrollChildren's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales Sydney, New South Wales, Australia.
Webster L SantosDepartment of Chemistry and VT Center for Drug Discovery, Virginia Tech, Blacksburg, VA, USA.
Kate Gr QuinlanSchool of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW, Australia.
Nigel TurnerSchool of Medical Sciences, University of New South Wales, Sydney, NSW, Australia.
Daniel J FazakerleyCharles Perkins Centre, School of Life and Environmental Sciences, University of Sydney, Australia.
Naresh KumarSchool of Chemistry, University of New South Wales, Sydney, NSW, Australia.
Kyle L HoehnSchool of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW, Australia. Electronic address: k.hoehn@unsw.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A hallmark of cancer cells is their ability to reprogram nutrient metabolism. Thus, disruption to this phenotype is a potential avenue for anti-cancer therapy. Herein we used a phenotypic chemical library screening approach to identify molecules that disrupted nutrient metabolism (by increasing cellular oxygen consumption rate) and were toxic to cancer cells. From this screen we discovered a 1,4-Naphthoquinone (referred to as BH10) that is toxic to a broad range of cancer cell types. BH10 has improved cancer-selective toxicity compared to doxorubicin, 17-AAG, vitamin K3, and other known anti-cancer quinones. BH10 increases glucose oxidation via both mitochondrial and pentose phosphate pathways, decreases glycolysis, lowers GSH:GSSG and NAPDH/NAPD

Indexed as

BenzoquinonesCell Line, TumorCell SurvivalDoxorubicinGlycolysisHumansLactams, MacrocyclicMitochondriaNaphthoquinonesOxidative StressOxygen ConsumptionPhenotypeSmall Molecule LibrariesVitamin K 31,4-naphthoquinoneBenzoquinonesDoxorubicinLactams, MacrocyclicNaphthoquinonesSmall Molecule LibrariestanespimycinVitamin K 3Cancer metabolismMitochondriaPeroxiredoxinQuinone

Identifiers

PMID31743887
PMCPMC6861633

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.